Randomized, single-blinded, placebo-controlled, parallel-group trial to clarify the efficacy of 3 times nebulized Amphotericin B on cough symptoms in chronic cough patients with Bjerkandera adusta cultured

Randomized, single-blinded, placebo-controlled, parallel-group trial to clarify the efficacy of 3 times nebulized Amphotericin B on cough symptoms in chronic cough patients with Bjerkandera adusta cultured - Efficacy of multiple nebulized Amphotericin B on chronic cough cough with Bjerkandera adusta cultured

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010030

Enrollment

Registered

2013-02-20

Start date

2013-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic cough with basidiomycetous fungi cultured from their sputum or pharyngeal swab

Interventions

Nebulizer inhalation of 2.5 mg Amphotericin B for three times(day 1,3,5) Nebulizer inhalation of combination of 1.25 mg Amphotericin B and 0.25 mg Budesonide for three times(day 1,3,5)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with bronchodilator(a combination of oral clenbuterol and salbutamol inhalation at bedtime or when required) resistive cough lasting eight weeks or more with Bjerkandera adusta cultured.

Exclusion criteria

Exclusion criteria: 1) Patients having abnormal shadow on chest X-ray 2) Patients having wheezing audible 3) Patients having obstructive disorders in pulmonary function testing 4) Patients having severe complications 5) Patients having pulmonary tuberclosis

Design outcomes

Primary

Measure	Time frame
Changes in cough symptoms using Japanese version of LCQ scores, Cough-related laryngeal sensation questionnaire, value of FENO, capsaicin cough thresholds are evaluated.	—

Secondary

Measure	Time frame
The successful eradication of B.adusta cultured is estimated.	—

Countries

Japan

Contacts

Public ContactHaruhiko Ogawa

Ishikawa-ken Saiseikai Kanazawa Hospital. The Division of Pulmonary Medicine

saiseikh@po3.nsknet.or.jp076-266-1060

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026